Michael Lilly to Neoplasm Grading
This is a "connection" page, showing publications Michael Lilly has written about Neoplasm Grading.
Connection Strength
0.109
-
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193.
Score: 0.044
-
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 2019 Feb; 173(3):559-571.
Score: 0.039
-
Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7(10):e46737.
Score: 0.026